% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kbel:284647,
author = {M. Köbel and R. Z. Yang and E. Y. Kang and Z. Al-Shamma
and L. S. Cook and M. Kinloch and M. S. Carey and L. Hopkins
and G. S. Nelson and K. J. McManus and F. S. Vizeacoumar and
F. J. Vizeacoumar and A. Freywald and Y. Fu and D. E.
Reuss$^*$ and C.-H. Lee},
title = {{S}urvey of {NF}1 inactivation by surrogate
immunohistochemistry in ovarian carcinomas.},
journal = {Gynecologic oncology},
volume = {178},
issn = {0090-8258},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2023-02050},
pages = {80 - 88},
year = {2023},
abstract = {Inhibition of the MAPK pathway by MEK inhibitors (MEKi) is
currently a therapeutic standard in several cancer types,
including ovarian low-grade serous carcinoma (LGSC). A
common MAPK pathway alteration in tubo-ovarian high-grade
serous carcinoma (HGSC) is the genomic inactivation of
neurofibromin 1 (NF1). The primary objectives of our study
were to survey the prevalence of NF1 inactivation in the
principal ovarian carcinoma histotype as well as to evaluate
its associations with clinico-pathological parameters and
key biomarkers including BRCA1/2 status in HGSC.A recently
commercialized NF1 antibody (clone NFC) was orthogonally
validated on an automated immunohistochemistry (IHC)
platform and IHC was performed on tissue microarrays
containing 2140 ovarian carcinoma cases. Expression was
interpreted as loss/inactivated (complete or subclonal)
versus normal/retained.Loss of NF1 expression was detected
in 250/1429 $(17.4\%)$ HGSC including $11\%$ with subclonal
loss. Survival of NF1-inactivated HGSC patients was
intermediate between favorable BRCA1/2 mutated HGSC and
unfavorable CCNE1 high-level amplified HGSC. NF1
inactivation was mutually exclusive with CCNE1 high-level
amplifications, co-occurred with RB1 loss and occurred at
similar frequencies in BRCA1/2 mutated versus wild-type
HGSC. NF1 loss was found in 21/286 $(7.3\%)$ endometrioid
carcinomas with a favorable prognostic association (p =
0.048), and in 4/64 $(5.9\%)$ LGSC, mutually exclusive with
other driver events.NF1 inactivation occurs in a significant
subset of BRCA1/2 wild-type HGSC and a subset of LGSC. While
the functional effects of NF1 inactivation need to be
further characterized, this signifies a potential
therapeutic opportunity to explore targeting NF1
inactivation in these tumors.},
keywords = {High-grade serous carcinoma (Other) / NF1 (Other) / Ovarian
cancer (Other)},
cin = {B300 / HD01},
ddc = {610},
cid = {I:(DE-He78)B300-20160331 / I:(DE-He78)HD01-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37820398},
doi = {10.1016/j.ygyno.2023.09.016},
url = {https://inrepo02.dkfz.de/record/284647},
}